Search

Meeting Coverage:

American Glaucoma Society

AGS: 2020

Autonomous AI's Potential in Glaucoma

Michael D. Abramoff, MD, PhD

Show Description +

Michael D. Abramoff, MD, PhD, describes the potential advantages of autonomous AI in the glaucoma space, including cost savings and improvements in quality of care. Dr. Abramoff also overviews the risks and responsibilities associated with using this technology.

Posted: 1/28/2020

Keywords:

Artificial Intelligence

•

Glaucoma

•

Technology

Up Next

$Glaucoma in Post-Refractive Surgery Eyes$

Glaucoma in Post-Refractive Surgery Eyes

Sarwat Salim, MD

MIGS in the Highly Myopic Patient

MIGS in the Highly Myopic Patient

Constance Okeke, MD, MSCE

LiGHT: Efficacy and Cost Effectiveness

LiGHT: Efficacy and Cost Effectiveness

Gus Gazzard, MD, FRCOphth, Sarwat Salim, MD

Traditional Surgery in the Highly Myopic Patient

Traditional Surgery in the Highly Myopic Patient

Leon Herndon, MD

AI for the Detection of Glaucomatous Progression

AI for the Detection of Glaucomatous Progression

Tobias Elze, PhD

Glaucoma and the Ocular Surface

Glaucoma and the Ocular Surface

Laura A. Voicu, MD, Sarwat Salim, MD

MIGS in the Highly Hyperopic Patient

MIGS in the Highly Hyperopic Patient

Leonard K. Seibold, MD,

OHTS: 20-Year Follow-Up

OHTS: 20-Year Follow-Up

Eve Higginbotham, MD

Founding a Glaucoma Society

Founding a Glaucoma Society

M. Bruce Shields, MD, Sarwat Salim, MD

Classification and Staging of Glaucoma

Classification and Staging of Glaucoma

M. Bruce Shields, MD, Sarwat Salim, MD

Rapid Clinical Trials for Neuroprotection

Rapid Clinical Trials for Neuroprotection

Yvonne Ou, MD

MIGS in Kids

James D. Brandt, MD, Sarwat Salim, MD

Corneal Hysteresis and Glaucoma Surgery

Corneal Hysteresis and Glaucoma Surgery

Davinder S. Grover, MD, MPH

Back to All Videos

Autonomous AI's Potential in Glaucoma

Michael D. Abramoff, MD, PhD

Michael D. Abramoff, MD, PhD, describes the potential advantages of autonomous AI in the glaucoma space, including cost savings and improvements in quality of care. Dr. Abramoff also overviews the risks and responsibilities associated with using this technology.

Posted: 1/28/2020

Keywords:

Artificial Intelligence

•

Glaucoma

•

Technology

Please log in to leave a comment.

More From AGS: 2020 Coverage

OHTS: 20-Year Follow-Up

OHTS: 20-Year Follow-Up

Eve Higginbotham, MD

Founding a Glaucoma Society

Founding a Glaucoma Society

M. Bruce Shields, MD, Sarwat Salim, MD

Classification and Staging of Glaucoma

Classification and Staging of Glaucoma

M. Bruce Shields, MD, Sarwat Salim, MD

Rapid Clinical Trials for Neuroprotection

Rapid Clinical Trials for Neuroprotection

Yvonne Ou, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AGS: 2020.